Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $48.28 Analyst target: $87.25 Upside: 80.72%
AnaptysBio, Inc., a clinical-stage biotechnology company, is dedicated to developing therapeutic product candidates for inflammation and immuno-oncology indications. The company is headquartered in San Diego, California.
See the full interactive analysis & chart →Informational only — not investment advice.